WEEKLY GRAVITY SCAN REPORT
Therapy / wellness produced a clear recurrence this week. A named behavioral-health coverage-parity endpoint and a proposed transformed addiction-treatment pathway were assigned to regulatory and investigational technological steps. Real improvement was documented: a 457-person randomized study found 16-week benefit from a digital schizophrenia intervention, and a late-stage bipolar-mania trial met its primary goal. Yet the same window also showed an Alzheimer’s-psychosis trial missing its primary endpoint, low antipsychotic adherence in a historical first-episode cohort, uneven treatment response, continuing device evaluation, and unmet physical and behavioral care. These are concrete limits and harms, not a denial of the bounded clinical successes. All three precommitted checks were present.
P(THERAPY / WELLNESS SIGNATURE RECURS) ≈ 0.94 · RESULT HIT
Estimate basis: 17-scan record · forecast scored Saturday September 26, 2026 · confidence: MODERATE.
Assignment is grounded in source-stated arrival conditions, not symptom reduction alone. Axios (Sep. 21) reported a coverage-parity target: health plans covering behavioral-health services at the same level as physical-health care through further enforcement and rulemaking. NET Recovery (Sep. 23) stated a goal of transforming addiction treatment through a non-drug device and restoring patient choice; its proposed new stimulant-use indication remains investigational. These are named target conditions assigned to further regulatory and technological steps. CT-155 and the other symptom-reduction trials are evaluated as actual outputs and counter-evidence, not counted by themselves as completion promises.
PRESENT ✓The output was continuation-shaped. A 457-person digital-therapy trial reported a genuine 16-week result but studied an adjunct intervention with longer-term and implementation questions. An Alzheimer’s-psychosis Phase 2 study missed its prespecified primary significance threshold and its sponsor planned the next phase; a device obtained breakthrough designation, not authorization; an rTMS reanalysis separated four response trajectories requiring prospective validation; coverage parity moved through further enforcement and prospective rulemaking. The late-stage mania result was a real three-week success, but the reported endpoint does not establish durable post-treatment completion.
CONTINUATION-SHAPED ✓Fallout was observable independently of any absence-of-completion claim. A JAMA cohort of 11,889 commercially insured people with first-episode psychosis in 2013–2021 found only 19.1% met a defined one-year antipsychotic adherence threshold, with poor adherence associated with more emergency-department visits. An English NHS-data analysis reported excess premature deaths among people in specialist mental-health services. The Alzheimer’s-psychosis trial missed its primary endpoint (p=0.0603); current reporting described treatment-coverage gaps, while suicide-prevention reporting examined the limits of individual prediction and the need for direct safety interventions.
PRESENT ✓All three precommitted conditions were present. Material positive counter-evidence was retained. No MISS condition was triggered.
HIT| Organization | Item | Indicator | Value / observation | Date | URL |
|---|---|---|---|---|---|
| JAMA Network Open / first-episode psychosis | Treatment Adherence and Health Care Utilization After a First Episode of Psychosis | Fallout + continuation · classification carrier | Study of 11,889 commercially insured people aged 15–40 with first-episode psychosis in 2013–2021 found 19.1% met the one-year antipsychotic adherence threshold (PDC ≥0.8); greater adherence was associated with fewer emergency-department visits. Historical cohort, not a current population estimate. | Sep. 24, 2026 | Source |
| Acadia Pharmaceuticals / SEC | RADIANT Phase 2 remlifanserin trial in Alzheimer’s-disease psychosis | Assignment + outcome/fallout · classification carrier | Company-reported 60-mg dose missed its prespecified primary SAPS-H+D endpoint versus placebo (p=0.0603); a secondary CGI-S result was nominally positive (p=0.0077). The company stated plans to advance development. | Sep. 24, 2026 | Source |
| NET Recovery | FDA breakthrough-device designation for investigational stimulant-use-disorder stimulation technology | Assignment + continuation · classification carrier | Company announced breakthrough designation for its investigational stimulation device. A designation facilitates development and review; it is not marketing authorization or proof of clinical effectiveness. | Sep. 23, 2026 | Source |
| JAMA Network Open / rTMS | Dorsolateral Prefrontal rTMS Symptom Cluster Response Trajectories for Depression | Outcome variation + continuation + contrary · classification carrier | Reanalysis of 388 adults identified four response trajectories; final remission was 65.22% in the optimal-response group versus 0% in the minimal-response group. The differentiated trajectories require prospective validation; substantial remission in a subgroup is real. | Sep. 24, 2026 | Source |
| Axios / behavioral-health coverage | Mental-health parity coverage, network access and rulemaking | Access continuation + fallout · classification carrier | New reporting described disputed parity compliance, access and network gaps, and prospective enforcement/rulemaking. The underlying federal directive was dated Sep. 8 and is antecedent context, not a new source-window action. | Sep. 21, 2026 | Source |
| The Guardian / Rethink Mental Illness | NHS-data analysis of early mortality in severe mental illness | Fallout + corrective assignment · classification carrier | In an English analysis of adults under 75 referred to specialist mental-health services, all-cause premature death was 4.8 times higher than comparison population; physical-health care integration and prevention were identified as corrective targets. Underlying reporting period 2022–2024. | Sep. 20, 2026 | Source |
| KFF Health News | Suicide-prevention reporting on prediction limits and direct safety interventions | Therapeutic-assignment + intervention-continuation · classification carrier | Clinical reporting documented that individual suicide-risk prediction remains difficult and described prevention approaches that reduce access to lethal means and require ongoing safety and treatment work. Published Sep. 21. | Sep. 21, 2026 | Source |
| JAMA Network Open / CT-155 randomized study | Digital therapeutic for negative symptoms of schizophrenia | Positive clinical outcome + contrary · contextual/contrary | In 457 randomized adults, 16 weeks of CT-155 adjunct digital treatment improved negative-symptom severity against a digital control. A real randomized benefit; treatment remains condition- and duration-specific. | Sep. 25, 2026 | Source |
| Reuters / Johnson & Johnson | Caplyta meets main goal in late-stage bipolar mania study | Positive clinical outcome + contrary · contextual/contrary | Phase 3 study met the main mania endpoint; company reported roughly 46% clinical response versus 21% placebo over three weeks. The new use required further regulatory action. | Sep. 21, 2026 | Source |
| HCPLive / ProACt interim | Adjunctive cariprazine observations in major depressive disorder | Positive short-term observation + contrary · contextual/contrary | Interim observational data described early improvement through week 6 after treatment augmentation; interim, nonrandomized observations do not establish comparative or long-term outcomes. | Sep. 23, 2026 | Source |
Material counter-signal was present and weighed at full strength. In a randomized 457-person study, adjunct digital therapeutic CT-155 improved schizophrenia negative-symptom severity against digital control over 16 weeks. A Phase 3 bipolar-mania study of Caplyta met its primary endpoint; the company reported about 46% clinical response versus about 21% with placebo during three weeks. An rTMS reanalysis also reported 65.22% remission at the final treatment assessment in its favorable trajectory group, versus none in its minimal-response group. Those are genuine benefits and genuine remission for some patients; they are not erased by the HIT. W1 was assessed under the published test of stable, durable completion-side output within the domain—not a requirement for domain-wide success. The CT-155 study measured symptom improvement during a 16-week adjunct intervention, not sustained remission after treatment; the Caplyta report measured a three-week mania outcome, not durable post-treatment resolution; and the rTMS remission figures describe the end-of-treatment assessment, not demonstrated maintenance over time. Accordingly, this source window does not establish stable, durable completion-side output for those outcomes. They remain on the W1 runway at full evidentiary weight.
Promise and uptake were separated. The source-stated coverage-parity target and NET Recovery treatment-transformation/choice goal establish Assignment; an ordinary objective to reduce symptoms was not counted by itself as a completion promise. Actual outcomes were scored separately: a statistically significant 16-week adjunct digital-therapeutic outcome, a successful three-week mania endpoint, a Phase 2 primary miss despite a nominal positive secondary endpoint, measured historical adherence, treatment-response heterogeneity and continuing access/physical-health consequences. An FDA breakthrough designation is an expedited-development designation, not device clearance or evidence of established patient benefit.
Scan performed September 26 · latest included source September 25 · primary source window September 19–25 · report/publication date September 26. Source quality: 10 named public, dated items examined; 7 classification carriers and 3 contextual/contrary. Carrier set: JAMA Network Open adherence cohort; Acadia’s SEC-filed Phase 2 readout; NET Recovery’s dated FDA-designation statement; JAMA Network Open rTMS cohort; Axios coverage reporting; Guardian reporting on a UK NHS-data analysis; KFF Health News suicide-prevention reporting. Contextual/contrary: JAMA Network Open CT-155 randomized trial; Reuters on the positive Caplyta mania trial; HCPLive on interim adjunct-depression observations. The JAMA adherence study analyzes commercially insured patients from 2013–2021; it is not a measurement of the whole 2026 population. The UK mortality analysis concerns people under 75 receiving specialist mental-health services in England, not all patients globally. The September 21 Axios account discusses a September 8 directive as historical context; that earlier directive does not independently carry a current-window condition. No outside-window source is used as a new classification carrier. ROLLING 12-SCAN REVIEW: NOT DUE; last reviewed at Signal 14, no change. Rubric v2.1 · method: manual.
10 sources examined · 7 classification carriers · 3 contextual/contrary · rubric v2.1 · method: manual.
Forecast scored: P≈0.94 · 17-scan record basis · MODERATE confidence. Result: HIT. Next forecast: P≈0.96 that the assignment → continuation-shaped output → fallout signature recurs in spirituality / meaning by October 3, 2026. Basis: 18-scan record · confidence: MODERATE. This is a prospective record-derived recurrence forecast and is not evidence that the structural detection itself has been proven.
RUBRIC v2.1 · METHOD: MANUAL · NEXT ENTRY: SAT OCT 03 2026
The scan tracks the fallout. It does not prove the detection.